Deerfield Management Company, L.P. (Series C) Edgewise Therapeutics, Inc. Transaction History
Deerfield Management Company, L.P. (Series C)
- $5.38 Billion
- Q3 2024
A detailed history of Deerfield Management Company, L.P. (Series C) transactions in Edgewise Therapeutics, Inc. stock. As of the latest transaction made, Deerfield Management Company, L.P. (Series C) holds 1,781,006 shares of EWTX stock, worth $51.2 Million. This represents 0.88% of its overall portfolio holdings.
Number of Shares
1,781,006
Previous 2,874,586
38.04%
Holding current value
$51.2 Million
Previous $51.8 Million
8.18%
% of portfolio
0.88%
Previous 1.09%
Shares
3 transactions
Others Institutions Holding EWTX
# of Institutions
191Shares Held
100MCall Options Held
2.17MPut Options Held
410K-
Orbimed Advisors LLC San Diego, CA15MShares$432 Million9.45% of portfolio
-
Ra Capital Management, L.P. Boston, MA8.91MShares$256 Million3.32% of portfolio
-
Black Rock Inc. New York, NY6.02MShares$173 Million0.0% of portfolio
-
Baker Bros. Advisors LP New York, NY5.84MShares$168 Million1.67% of portfolio
-
Novo Holdings Hellerup, G75.55MShares$160 Million10.36% of portfolio
About Edgewise Therapeutics, Inc.
- Ticker EWTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 63,171,700
- Market Cap $1.82B
- Description
- Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has c...